Suppr超能文献

卵巢癌患者中ROR1的表达及其与化疗反应和预后的关系。

ROR1 expression in ovarian cancer patients and its association with chemotherapy response and prognosis.

作者信息

Zhang Yan, Wang Wei, Xu Lian, Huang Liujing, Qin Tian, Kang Ling, Huang Qin

机构信息

Department of Pathology, West China Second University Hospital, Sichuan University Chengdu 610000, Sichuan, PR China.

Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University Chengdu 610000, Sichuan, PR China.

出版信息

Int J Clin Exp Pathol. 2025 May 15;18(5):179-190. doi: 10.62347/EHAI6164. eCollection 2025.

Abstract

OBJECTIVE

To investigate the expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in ovarian cancer tissues and its correlation with clinicopathologic features, chemotherapy sensitivity, and prognosis in patients with ovarian cancer.

METHODS

Paraffin tissue blocks were collected from 227 ovarian cancer patients, and immunohistochemical (IHC) staining was performed to analyze the expression of ROR1. The associations between ROR1 expression and clinicopathologic features, treatment response, and prognosis were evaluated.

RESULTS

ROR1 expression and tumor load: higher expression of ROR1 was associated with a heavier tumor load in ovarian cancer patients. ROR1 and chemotherapy: the expression of ROR1 was significantly higher in patients who underwent interval debulking surgery (IDS) compared to primary debulking surgery (PDS) and subsequent chemotherapy (SSC). This suggests that chemotherapy may promote increased ROR1 expression in tumor tissues. Additionally, a trend of higher ROR1 expression was observed in platinum-sensitive patients. Nuclear expression in clear cell ovarian cancer: positive nuclear expression of ROR1 was unexpectedly detected in clear cell ovarian cancer, suggesting a link between ROR1 nuclear translocation and poor prognosis.

CONCLUSION

ROR1 expression may be related to treatment strategy and history of platinum-based chemotherapy in ovarian cancer patients. Targeting ROR1 could represent a promising therapeutic strategy for the treatment of ovarian cancer. Further studies are needed to elucidate the role of ROR1 nuclear translocation in prognosis.

摘要

目的

探讨受体酪氨酸激酶样孤儿受体1(ROR1)在卵巢癌组织中的表达及其与卵巢癌患者临床病理特征、化疗敏感性和预后的相关性。

方法

收集227例卵巢癌患者的石蜡组织块,采用免疫组织化学(IHC)染色分析ROR1的表达。评估ROR1表达与临床病理特征、治疗反应和预后之间的关联。

结果

ROR1表达与肿瘤负荷:ROR1表达较高与卵巢癌患者肿瘤负荷较重相关。ROR1与化疗:与初次肿瘤细胞减灭术(PDS)及后续化疗(SSC)相比,接受间歇性肿瘤细胞减灭术(IDS)的患者ROR1表达显著更高。这表明化疗可能促进肿瘤组织中ROR1表达增加。此外,在铂敏感患者中观察到ROR1表达有升高趋势。透明细胞卵巢癌中的核表达:在透明细胞卵巢癌中意外检测到ROR1核阳性表达,提示ROR1核易位与预后不良之间存在关联。

结论

ROR1表达可能与卵巢癌患者的治疗策略及铂类化疗史有关。靶向ROR1可能是治疗卵巢癌的一种有前景的治疗策略。需要进一步研究阐明ROR1核易位在预后中的作用。

相似文献

1
ROR1 expression in ovarian cancer patients and its association with chemotherapy response and prognosis.
Int J Clin Exp Pathol. 2025 May 15;18(5):179-190. doi: 10.62347/EHAI6164. eCollection 2025.
2
Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17266-71. doi: 10.1073/pnas.1419599111. Epub 2014 Nov 19.
3
ROR1 expression correlated with poor clinical outcome in human ovarian cancer.
Sci Rep. 2014 Jul 24;4:5811. doi: 10.1038/srep05811.
4
Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1).
Medicina (Kaunas). 2022 Dec 17;58(12):1867. doi: 10.3390/medicina58121867.
5
A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo.
Biomed Pharmacother. 2019 Nov;119:109420. doi: 10.1016/j.biopha.2019.109420. Epub 2019 Sep 16.
6
Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.
Clin Cancer Res. 2017 Jun 15;23(12):3061-3071. doi: 10.1158/1078-0432.CCR-16-2083. Epub 2016 Nov 16.
7
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
8
Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells.
Oncotarget. 2017 Oct 7;8(55):94210-94222. doi: 10.18632/oncotarget.21618. eCollection 2017 Nov 7.
9
The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models.
Ther Adv Med Oncol. 2025 Apr 21;17:17588359251332471. doi: 10.1177/17588359251332471. eCollection 2025.

本文引用的文献

1
Novel humanized monoclonal antibodies against ROR1 for cancer therapy.
Mol Cancer. 2024 Aug 13;23(1):165. doi: 10.1186/s12943-024-02075-y.
2
Discovery of Novel Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors for Cancer Treatment.
J Med Chem. 2024 Jul 11;67(13):10655-10686. doi: 10.1021/acs.jmedchem.4c00175. Epub 2024 Jun 24.
3
Heterogeneous Profile of ROR1 Protein Expression across Tumor Types.
Cancers (Basel). 2024 May 15;16(10):1874. doi: 10.3390/cancers16101874.
4
Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer.
Int Immunopharmacol. 2024 May 30;133:112157. doi: 10.1016/j.intimp.2024.112157. Epub 2024 Apr 27.
5
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
Gynecol Oncol. 2024 May;184:51-56. doi: 10.1016/j.ygyno.2024.01.027. Epub 2024 Jan 28.
6
Clinical and translational advances in ovarian cancer therapy.
Nat Cancer. 2023 Sep;4(9):1239-1257. doi: 10.1038/s43018-023-00617-9. Epub 2023 Aug 31.
8
ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity.
Cell Death Discov. 2023 Jul 3;9(1):222. doi: 10.1038/s41420-023-01527-6.
9
ROR1: an orphan becomes apparent.
Blood. 2022 Oct 6;140(14):1583-1591. doi: 10.1182/blood.2021014760.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验